Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Factor has launched the new One aero race bike, claimed to be the “fastest UCI-legal road bike in the world”. Formerly known as the ‘Prototype’, which made its racing debut under select Israel–Premier ...

DNA Ginkgo Bioworks Holdings, Inc.

Factor meals provides fully prepared meals designed by registered dietitians. Meal delivery is a convenient meal solution for busy individuals looking to maintain a balanced diet. Our testers tried ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...

Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Anthony Battle is a CERTIFIED FINANCIAL PLANNER™ professional. He earned the Chartered Financial Consultant® ...

TIOBE Index for December 2025: Top 10 Most Popular Programming Languages Your email has been sent December’s TIOBE Index lands with a quieter top tier but a livelier shuffle just beneath it. The main ...